Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Pass Below 200 Day Moving Average – Time to Sell?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $31.25 and traded as low as $27.50. Lakefront Biotherapeutics American Depositary Shares shares last traded at $28.11, with a volume of 148,929 shares.

Analysts Set New Price Targets

LKFT has been the topic of several recent research reports. Wall Street Zen downgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. UBS Group restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Zacks Research lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Royal Bank Of Canada lifted their price target on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the company a “sector perform” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Up 2.2%

The firm has a market capitalization of $1.85 billion, a P/E ratio of -19.94 and a beta of 0.26. The business’s 50 day moving average is $28.38 and its two-hundred day moving average is $31.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The company had revenue of $1.06 billion during the quarter. As a group, equities analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Western Standard LLC acquired a new stake in Lakefront Biotherapeutics American Depositary Shares in the fourth quarter worth approximately $1,046,000. UBS Group AG raised its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% in the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after buying an additional 196,445 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 2,490.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock worth $49,083,000 after buying an additional 1,362,229 shares in the last quarter. Kotler Kevin acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the fourth quarter valued at $2,943,000. Finally, Jane Street Group LLC lifted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after buying an additional 115,946 shares during the period. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.